PartnerTx

Partner Therapeutics (PTx) is a commercial biotech committed to improving the lives of patients with cancer and other serious diseases.

[PartnerTx @PartnerTx]

IMREPLYS® (sargramostim, rhu GM-CSF) approved by the European Commission for treatment of patients of all ages acutely exposed to myelosuppressive doses of radiation with Haematopoietic Sub-syndrome of Acute Radiation Syndrome (H-ARS). Press release: https://t.co/DRVGDfUlNO

[PartnerTx @PartnerTx]

IMREPLYS® (sargramostim, rhu GM-CSF) recommended for EU approval by the CHMP to treat exposure to haematopoietic acute radiation syndrome. Read more in the press release: https://t.co/zNwoFa4uu6

[THOR_Network @theTHORnetwork]

🧠 Sponsor Spotlight: @PartnerTx On #NationalHealthcareDecisionsDay, we recognize the importance of informed, timely trauma care. Thanks to @PartnerTx for advancing immunotherapy that supports decision-making in critical trauma settings.

🌐 https://t.co/waw61z4ILr

#THOR #RDCR

[PartnerTx @PartnerTx]

@BARDA and Partner Therapeutics continue partnership around development of stratification approach to inform LEUKINE® (sargramostim, rhu GM-CSF) treatment for sepsis. Read more in the press release: https://t.co/FJkZBjEDml

[PartnerTx @PartnerTx]

Partner Therapeutics supports #ChildhoodCancerAwareness Month. We honor the children and families impacted by childhood cancer as well as the clinicians and researchers.

[PartnerTx @PartnerTx]

Please join #RadRes2024 Poster Session 1 - 9/15 at 1:45-2:30pm MST for "The lethality of radiation-induced sepsis and associated immune dysregulation highlight the importance of restoring lymphocyte and monocyte levels and function after total body irradiation."@RRS_RadRes #GMCSF

[PartnerTx @PartnerTx]

Join us at ERRS as Dr. Melanie Doyle-Eisele presents "Sargramostim improves survival and recovery from pancytopenia in [non-human primate] total body irradiation model with minimal supportive care" on Tues Sept 10 at 15:15 WEST. #sargramostim #GMCSF #radiation #myelosuppression

[Lovelace Biomedical @Lovelace_Biomed]

Next week, join Melanie Doyle-Eisele and Dave Revelli as they present at the 48th Annual ERRS Meeting. They will be presenting with Partner Therapeutics. Contact us at [email protected] or reach out at https://t.co/0pz8bnFhyE to schedule a meeting.

[PartnerTx @PartnerTx]

Partner Therapeutics supports #BloodCancerAwarenessMonth and #WorldLeukemiaDay. Together we can raise awareness. #LeukemiaAwareness

[Acute Leukemia Advocates Network (ALAN) @AcuteLeuk]

September is a very important month for raising awareness. September is Blood Cancer Awareness Month.

#BeLeukemiaAware
#WLD24 #BeLeukemiaAware #WLD24 #WorldLeukemiaDay #BloodCancerAwarenessMonth #yourenotalone #Leukemia #PatientAdvocacy #Alan #advocacy #Awareness

[PartnerTx @PartnerTx]

Our heartfelt condolences on the loss of a pioneer in immunotherapy and melanoma research, Jeffrey S. Weber, PhD, MD. We celebrate his numerous contributions for patients and impact on clinical practice.

[Melanoma Research Foundation @CureMelanoma]

The Melanoma Research Foundation joins the melanoma community in expressing our profound condolences on the recent passing of Jeffrey S. Weber, MD, PhD. Dr. Weber was an internationally recognized and trailblazing pioneer in cancer immune therapy and melanoma and made countless contributions to these fields throughout his remarkable career. As an immunotherapy expert, Dr. Weber’s investigations and research findings have brought innovative advancements in melanoma treatment from the laboratory to clinical practice. Collectively, Dr. Weber’s contributions have greatly impacted the entire melanoma community and have enabled tremendous progress for countless patients, survivors and caregivers.

Dr. Weber was the esteemed deputy director of the Perlmutter Cancer Center and codirector of the Melanoma Research Program at @nyulangone. Prior to this most recent role, Dr. Weber also held leadership positions at @MoffittNews and @uscnorris. He was a recognized leader in forging collaborative partnerships between basic scientists and clinical and translational investigators to advance cancer care. Throughout his decades long career, Dr. Weber led multiple practice changing clinical trials including the CheckMate 238 Phase III adjuvant nivolumab trial in stage III melanoma that established the first adjuvant use of anti-PD-1 antibodies. He also presented on the randomized Phase II trial of pembrolizumab and a personalized mRNA cancer vaccine compared to pembrolizumab alone in patients with melanoma. This was a landmark study in showing the first time randomized clinical data supporting the efficacy of a vaccine in preventing cancer relapse.

The MRF is incredibly honored and indebted to Dr. Weber for his many years of service to our community. In 2021, Dr. Weber helped produce a series of Animated Patient Videos that helped synthesize a variety of melanoma topics such as understanding, diagnosing and treating melanoma, an overview of genetic mutations of melanoma and TIL cell therapy and clinical trials for melanoma. This series continues to benefit melanoma patients, caregivers and survivors across the spectrum of their melanoma journey. In addition to his countless contributions to the melanoma patient community, Dr. Weber also helped steer the melanoma scientific community having served on the MRF’s Scientific Advisory Council and its Breakthrough Consortium – a network of 23 centers of excellence in melanoma that collaborate to accelerate the research and development of the most promising therapies in melanoma treatment. Dr. Weber served as an MRF grant reviewer and grant mentor and reviewed patient education materials. In 2021, the MRF honored Dr. Weber with its Humanitarian Award at that year’s New York City annual gala for his exceptional contributions to melanoma detection and treatment.

MRF’s Board Chair, Doug Brodman, offers, “It is with great sorrow that we have heard of Jeff's passing. Jeff was a passionate doctor and researcher who had an immeasurable impact on the melanoma field. His work had an enormous impact on the survivorship of many melanoma patients, including myself. His legacy and work will carry on with all those he has touched personally through his career's work.”

Our deepest condolences are extended to the family, friends, colleagues and patients of Dr. Weber’s and the countless cancer community members whose lives have been touched by his inspirational contributions.

[PartnerTx @PartnerTx]

Partner Therapeutics is excited to attend the Military Health Systems Research Symposium. Visit us at Booth #606. #MHSRS2024

[Military Health System @MilitaryHealth]

Day one of #MHSRS2024 is officially underway in Orlando, Florida. The @DeptofDefense’s premier meeting for military medical research, advancing military-unique research and development.

Follow along as we share key highlights and news from this incredible annual conference.

[PartnerTx @PartnerTx]

Congratulations to the Task Force on the first published guidelines for the diagnosis and management of #pulmonaryalveolarproteinosis.

[ERS @EuroRespSoc]

New Guideline now available!

The ‘ERS guidelines for the Diagnosis and Management of Pulmonary Alveolar Proteinosis’ is a diagnostic and management guideline aiming to provide guidance to physicians managing patients with PAP

Access the guideline now: https://t.co/XAfhjCfMEp

[PartnerTx @PartnerTx]

@PartnerTx is honored to sponsor the 2024 @PAP_Foundation Golfing for a Cure Charity Golf Tournament. #PAPawareness

[Pap Foundation @PAP_Foundation]

The 2024 Golfing for a Cure Charity Golf Tournament was a huge success! A whopping 103 golfers helped us to raise over $11,000 for the PAP Foundation⛳😄 Thank you to everyone who made this day happen, especially Steve Park. Thank you also to our sponsors for their support

[PartnerTx @PartnerTx]

Thank you to the patients, families, and investigators for your continued commitment to advance melanoma research #melanoma #cancerresearch #immunotherapy #ipilumumab #nivolumab #sargramostim #GMCSF
Learn more about this important trial: https://t.co/GCQ1kYT9KO

[ECOG-ACRIN Cancer Research Group @eaonc]

#ClinicalTrial EA6141 is testing combination therapy with ipilimumab, nivolumab, & sargramostim in advanced #melanoma. As May is #MelanomaAwarenessMonth, learn more about this important trial: https://t.co/iyi0RzXgbu cc: @ATarhiniMDPhD, @df_hcc #MelanomaAwareness

[PartnerTx @PartnerTx]

Excited to see continued investigation and literature of Leukine with immune checkpoint inhibitors for patients with #melanoma and GI immune-related adverse effects.
Press Release: https://t.co/s5sUa0P6Z7
#sargramostim #GMCSF #immunotherapy #ipilumumab #nivolumab #irAE

[PartnerTx @PartnerTx]

Investigators of the EA6141 phase 2/3 trial are exploring #nivolumab, #ipilimumab, and #sargramostim for patients with unresectable stage III or stage IV #melanoma.Additional details from the principal investigator: https://t.co/ATnv7ZWj6B #cancerresearch

[PartnerTx @PartnerTx]

Sargramostim received Japanese PDMA approval as Sargmalin® to treat autoimmune pulmonary alveolar proteinosis. Sargramostim to be manufactured by @PartnerTx and marketed by Nobelpharma Co. Ltd. #aPAP #sargramostim #GMCSF #Japan

Press release: https://t.co/RMZJB3CD6H

[PartnerTx @PartnerTx]

Pricing implications in the US on small biotechs requires close management of gross to net. Join Jake McDowell, VP and Head of Market Access and Pricing at @PartnterTX at the 2024 World EPA Congress in Amsterdam on March 12-13 to discuss.

https://t.co/R2M92H4xse

#EPAConf

[PartnerTx @PartnerTx]

Today is Rare Disease Day 2024. We are pleased to support research in this important area through sponsorship of the Rare Disease Clinical Trials Conference in Dublin, Ireland. #ShowYourStripes #RareDiseaseDay

[Rare Disease Clinical Trial Network, Ireland @rare_trial]

RARE DISEASE CLINICAL TRIALS CONFERENCE 🔬🧬

Join global experts, researchers and advocates to explore the forefront of rare disease clinical research

📍The Grand Hotel, Malahide, Dublin, Ireland
🗓️ 29 Feb - 1 March 2024
👥 All welcome!

REGISTER HERE: https://t.co/aqxUbkunb4

[PartnerTx @PartnerTx]

Well done, authors, on “Sargramostim for Prophylactic Management of Gastrointestinal Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy for Cancer.” Read full text: https://t.co/RYeAkBic1L #cancer #irAE #immunotherapy #sargramostim #GMCSF

[Cancers MDPI @Cancers_MDPI]

🧐Check out the #Review “Sargramostim for Prophylactic Management of Gastrointestinal Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy for Cancer”
📜Read more here: https://t.co/bNe8iOCgvA
#sargramostim #GMCSF #irAE

[PartnerTx @PartnerTx]

Congratulations authors on “GM-CSF, G-CSF, or no cytokine therapy with anti-GD2 #immunotherapy for high-risk #neuroblastoma” highlighting the importance of combination #sargramostim & anti-GD2 #mAbs #dinutuximab #naxitamab https://t.co/5CGfTuwj6R Read more:https://t.co/VSEuaO1jKL